GLPwatch
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
NCT01237119 · Completed
Last updated 2026-05-28This clinical trial tested the drug liraglutide in adults with non-alcoholic steatohepatitis to see if it improves liver tissue changes.
Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 52 people
Who can join Ages 18–70 · all sexes
Timeline Started 2010-08 · est. completion 2014-07
Where 1 site · United Kingdom
What this study is testing ClinicalTrials.gov NCT01237119 ↗
Description as written by the study sponsor.
The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough to warrant further investigation.
Treatments tested
- Liraglutide also known as Victoza Drug
1.8 mg once daily, subcutaneous injection
- Liraglutide-placebo Other
1.8 mg once-daily, subcutaneous injection
| Main thing measured | Liver Histological improvement |
|---|---|
| Sponsor | University of Birmingham |
| Conditions studied | Nonalcoholic Steatohepatitis |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01237119 ↗